NK Cells Mediate Flt3 Ligand-induced Protection of Dendritic Cell Precursors In Vivo from the Inhibition by Prostate Carcinoma in the Murine Bone Marrow Metastasis Model

Journal of Immunotherapy

Volumn 26, Issue 6, 2003, Pages 468-472

  Tourkova, Irina L ^a   Yamabe, Kazuo ^b   Chatta, Gurkamal ^a   Shurin, Galina V ^a   Shurin, Michael R ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Saiseikai Tondabayashi Hospital   (Japan)

^c Clinical Immunopathology   (United States)

Author keywords

Bone marrow metastases; Dendritic cells; flt3 ligand; Immunosuppression; Mixed leukocyte reaction; Prostate cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTIBIOTIC G 418; B7 ANTIGEN; CD86 ANTIGEN; FLT3 LIGAND; GANCICLOVIR; GLYCOPROTEIN P 15095; GROWTH FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4; UNCLASSIFIED DRUG; ZEOCIN; ZEOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW; BONE MARROW CELL; BONE MARROW METASTASIS; CANCER CELL; CANCER INHIBITION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL PROTECTION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; DENDROPOIESIS; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; MURIDAE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; SCID MOUSE; STATISTICAL SIGNIFICANCE; STEM CELL; T LYMPHOCYTE; WILD TYPE;

ANIMALS; BONE MARROW NEOPLASMS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; KILLER CELLS, NATURAL; MALE; MEMBRANE PROTEINS; MICE; PHENOTYPE; PROSTATIC NEOPLASMS; STEM CELLS; TRANSFECTION;

EID: 0242389542     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200311000-00002     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
2. Shurin MR, Gabrilovich DI. Regulation of dendritic cell system by tumor. Cancer Res Ther Control. 2001;11:65-78.
3. Stockwin LH, McGonagle D, Martin IG, et al. Dendritic cells: immunological sentinels with a central role in health and disease. Immunol Cell Biol. 2000;78:91-102.
4. Gunzer M, Janich S, Varga G, et al. Dendritic cells and tumor immunity. Semin Immunol. 2001;13:291-302.
5. Troy A, Davidson P, Atkinson C, et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol. 1998;160:214-219.
6. Pirtskhalaishvili G, Shurin GV, Esche C, et al. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer. 2000;83:506-513.
7. Pirtskhalaishvili G, Shurin GV, Gambotto A, et al. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol. 2000;165:1956-1964.
8. Rini BI, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2001;3:418-423.
9. Shurin MR, Pandharipande PP, Zorina TD, et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol. 1997;179:174-184.
10. Lynch DH. Induction of dendritic cells (DC) by Flt3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit Rev Immunol. 1998;18:99-107.
11. Favre-Felix N, Martin M, Maraskovsky E, et al. Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer. 2000;86:827-834.
12. Ciavarra RP, Somers KD, Brown RR, et al. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res. 2000;60:2081-2084.
13. Peron JM, Esche C, Subbotin VM, et al. FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol. 1998;161:6164-6170.
14. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5:405-411.
15. Okada H, Giezeman-Smits KM, Tahara H, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 1999;6:219-226.
16. Pear WS, Nolan GP, Scott ML, et al. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392-8396.
17. Tourkova IL, Yurkovetsky ZR, Shurin MR, et al. Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. Immunol Lett. 2001;78:75-82.
18. Sombroek CC, Stam AG, Masterson AJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 2002;168:4333-4343.
19. Aalamian M, Pirtskhalaishvili G, Nunez A, et al. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate. 2001;46:68-75.
20. Averbook BJ, Schuh JL, Papay R, et al. Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother. 2002;25:27-35.
21. Moghaddami M, Swart B, Reynolds P, et al. Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate. Immunol Cell Biol. 2002;80:370-381.